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Brief summary: This is an update of existing definitions of CMV disease for use in 
clinical trials. The main changes include a “probable disease” category and the use of 
NAT in some disease category  
 
Abstract 
Cytomegalovirus (CMV) infection and disease are important causes of morbidity and 
mortality in transplant recipients. For the purpose of developing consistent reporting of 
CMV outcomes in clinical trials, definitions of CMV infection and disease were 
developed and most recently published in 2002. Since then there have been major 
developments in its diagnosis and management. Therefore, the CMV Drug 
Development Forum consisting of scientists, clinicians, regulators, and industry 
representatives has produced an updated version incorporating recent knowledge with 
the aim to support clinical research and drug development. The main changes compared 
to previous definitions are the introduction of a “probable disease” category and to 
incorporate quantitative nucleic acid testing (NAT) in some end-organ disease 
categories. As the field evolves, the need for updates of these definitions is clear and 
collaborative efforts between scientists, regulators, and industry can provide a platform 
for this work.  
 at California D


















Cytomegalovirus (CMV) infection and disease are important causes of morbidity and 
mortality in transplant recipients. For the purpose of developing consistent reporting of 
CMV outcomes in clinical trials, definitions of CMV infection and disease were initially 
developed and published as part of the proceedings of the 4th International CMV 
Conference in Paris in 1993 [1], and these were subsequently updated in 1995 [2] and 
most recently in 2002 [3]. These definitions have since been used in many published 
clinical trials.  
During the last two decades, major advances have been made regarding the diagnosis 
and management of CMV in transplant patients. These advances have been made 
possible through the development of new diagnostic techniques for the detection of the 
virus and through the performance of prospective clinical trials that evaluated the 
efficacy and safety of novel antiviral agents. Therefore, the aim of this report from the 
“CMV Drug Development Forum” (http://www.hivforum.org/projects/drug-
development/cmv) is to update the published definitions of CMV infection and disease, 
taking into account the current state of knowledge in this field recognizing that more 




The “CMV Drug Development Forum” was created in 2014 and includes US, European, 
and Canadian experts on transplantation, transplant infectious disease, and clinical 
virology, regulators from the US Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA), and representatives of the pharmaceutical and 
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diagnostic industry. The CMV Forum is based on the Forum for Collaborative HIV 
Research model: a neutral, independent venue for all stakeholders to engage in dialogue 
and deliberation to advance regulatory science in disease specific areas [4, 5]. 
From the members of the CMV Forum, a Disease Definitions Working Subgroup was 
formed which reviewed the previously published document and proposed changes. The 
main changes were to introduce a “probable disease” category and to incorporate 
nucleic acid testing (NAT) in some end-organ disease categories.  These changes were 
discussed and approved at a meeting for the entire CMV Forum. The subgroup 
addressed the received comments and the updated document was presented at a second 
CMV Forum meeting and issues without consensus were voted upon. The definitions in 
this report were developed for application to solid organ transplant (SOT) and 
hematopoietic stem cell transplant (HSCT) recipients but can also, as appropriate, be 
applied to other immunocompromised individuals.  
 
CMV disease consists of “end-organ disease” and CMV syndrome. To define “proven 
CMV end-organ disease”, the presence of appropriate clinical symptoms and/or signs 
are required together with documentation of CMV in tissue from the relevant organ by 
histopathology, virus isolation, rapid culture, immunohistochemistry, or DNA 
hybridization unless there are data supporting that other materials can be accepted as 
having similar significance. It is recognized that high viral DNA-levels detected with 
quantitative NAT, such as polymerase chain reaction (PCR), in tissue from the relevant 
organ likely represent CMV disease and could therefore be accepted as “possible CMV 
end-organ disease” especially when blood sampled at the same time does not contain 
CMV DNA. However, due to the lack of studies, viral load cut-off levels have not yet 
been defined and will need to be assessed when new evidence becomes available.  
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There is only one clinical condition (CMV retinitis) where the symptoms and/or signs 
are sufficiently characteristic to allow a diagnosis of proven disease, even without 
testing for CMV in a tissue sample. The presence of CMV in the blood, together with 
symptoms and/or signs, is not sufficient for the definition of either proven or probable 
CMV disease at any other site, with the exception of CMV-syndrome in SOT patients, 
but can be used for further research in cohort studies as a definition of possible CMV 
disease. In this situation, methods for exclusion of other causes of the clinical symptoms 
and/or signs need to be clearly defined. The assessment of the response to anti-CMV 
therapy might also be considered to increase the likelihood for CMV as the cause of the 
symptoms and/or signs. However, it is recognized that, unless an antiviral drug with 
activity solely against CMV is used, other viral infections might also respond to broad 
spectrum antiviral therapy. Furthermore, from a regulatory perspective, response to 
therapy should not be used as a study endpoint or element in a composite study 
endpoint.  
The presence of co-pathogens, such as Aspergillus species together with typical 
radiologic signs of Aspergillus pneumonia would indicate fungal pneumonia, although a 
role of CMV cannot be conclusively excluded if the criteria for CMV disease are 
otherwise met. It is therefore recommended that studies report separately cases where 
CMV disease is found with or without co-pathogens with details given on the co-
pathogens.   
 
Definitions of CMV infection 
CMV Infection: “CMV infection” is defined as virus isolation or detection of viral 
proteins (antigens) or nucleic acid in any body fluid or tissue specimen. It is 
recommended that both the source of the specimens tested (e.g., plasma, serum, whole 
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blood, peripheral blood leukocytes (PBL), cerebrospinal fluid (CSF), bronchoalveolar 
lavage (BAL) fluid , urine, or tissue) and the diagnostic method used be described 
clearly.  
CMV Replication: The term replication can be used to indicate evidence of viral 
multiplication and is sometimes used instead of CMV infection.  
Primary CMV Infection: Primary CMV infection" is defined as the first detection of 
CMV infection in an individual who has no evidence of CMV exposure before 
transplantation. It is recognized that severely immunocompromised individuals such as 
transplant patients might not develop CMV specific antibodies.  
Recurrent CMV Infection: “Recurrent infection” is defined as new CMV infection in a 
patient with previous evidence of CMV infection, which has not had virus detected for 
an interval of at least 4 weeks during active surveillance. Recurrent infection may result 
from reactivation of latent virus (endogenous) or reinfection (exogenous). It is 
recognized that CMV specific antibodies can be passively transferred by blood products 
or immune globulin administration. For practical purposes, presence or absence of 
CMV specific antibodies by serology can be used as acceptable estimates of previous 
CMV exposure to classify patients for entry into clinical trials. 
CMV Reinfection. “Reinfection” is defined as detection of a CMV strain that is distinct 
from the strain that caused the initial infection.  
CMV Reactivation. CMV reactivation is likely if the 2 viral strains (prior and current 
strain) are found to be indistinguishable either by sequencing specific regions of the 
viral genome or by using a variety of molecular techniques that examine genes known 
to be polymorphic.   
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CMV detection in blood 
Several specific definitions for CMV detection in blood are recommended. It should be 
noted that evidence suggests that the detection of virus, antigen, or DNA in blood does 
not mean that CMV is replicating in blood. 
Viremia. “Viremia” is defined as the isolation of CMV by either standard or rapid 
culture techniques. These techniques are, however, rarely used today for monitoring of 
transplant recipients 
Antigenemia. “Antigenemia” is defined as the detection of CMV pp65 antigen in PBL. 
DNAemia. “DNAemia” is defined as the detection of CMV DNA in samples of plasma, 
serum, whole blood, isolated PBL or in buffy-coat specimens. There are several 
techniques available for the detection and quantitation of CMV DNAemia. It is strongly 
recommended that the nucleic acid amplification techniques have been calibrated to a 
standard calibrator, such as the WHO International Standard for Human CMV [6].  
RNAemia. “RNAemia” is defined as the detection of CMV RNA in samples of plasma, 
serum, whole blood, isolated PBL or in buffy-coat specimens. These techniques are not 
commonly used for monitoring of transplant patients despite having the theoretical 
advantage of documenting transcription of the genomic sequence. 
 
Definitions of CMV disease 
 
CMV Pneumonia:  
Proven disease requires clinical symptoms and/or signs of pneumonia such as new 
infiltrates on imaging, hypoxia, tachypnea, and/or dyspnea combined with CMV 
documented in lung tissue by virus isolation, rapid culture, histopathology, 
immunohistochemistry, or DNA hybridization techniques.  
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Probable CMV pneumonia is defined as the detection of CMV by viral isolation, rapid 
culture of BAL fluid, or the quantitation of CMV DNA in BAL fluid combined with 
clinical symptoms and/or signs of pneumonia. A definite cut-off for CMV DNA load 
cannot be established at the present time. The cut-off is likely to vary between different 
patients, how the BAL procedure and processing is performed, and the assay used for 
CMV DNA quantitation. Furthermore, CMV DNA levels may vary considerably 
between patients with varying degrees of severity of CMV pneumonia, which may 
impact the predictive values of any cut-off. It should be recognized that CMV shedding 
in the lower respiratory tract does occur and therefore a low CMV DNA load might well 
represent asymptomatic infection [7]. The likelihood for CMV pneumonia increases 
with increasing DNA viral load. In one study in HSCT patients, CMV viral load >200-
500 IU/ml in BAL fluid was likely (with a positive predictive value of ~50% based on 
disease prevalence figures of approximately 10% among patients at risk for CMV 
pneumonia undergoing BAL testing) to represent pneumonia in HSCT recipients (M 
Boeckh, manuscript in preparation), while lower levels were likely indicating 
pulmonary shedding. Data from lung transplant patients suggest that the viral load in 
BAL fluid in patients with CMV  pneumonia  is approximately 1.5 log10 higher than 
viral load in patients with detectable CMV DNA in BAL fluid without evidence of 
CMV pneumonia (a cut-off of 5500 IU/mL had a sensitivity of 91% and a specificity of 
75%) (Lodding et al; abstract ID week 2015). On the other hand, a negative CMV DNA 
test in the BAL fluid has a negative predictive value close to 100% and therefore 
excludes the possibility of CMV pneumonia. The use of quantitative PCR on biopsies is 
an evolving field. Presently, these findings could be defined as possible CMV 
pneumonia. 
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CMV Gastrointestinal Disease:  
Proven disease requires upper and/or lower gastrointestinal (GI)-symptoms plus 
macroscopic mucosal lesions plus CMV documented in tissue by histopathology, virus 
isolation, rapid culture, immunohistochemistry or DNA hybridization techniques. 
Studies should give information regarding the presence or absence of gut Graft-vs-Host 
disease (GVHD) in HSCT recipients. 
Probable GI disease requires upper and/or lower GI-symptoms and CMV documented 
in tissue but without the requirement for macroscopic mucosal lesions. Studies should 
give information regarding the presence or absence of gut GVHD in HSCT recipients. 
CMV documented in blood by NAT (e.g., PCR) or antigenemia or CMV documented 
by PCR from tissue biopsies is not sufficient for the diagnosis of CMV GI-disease. The 
use of quantitative PCR on gut biopsies is an evolving field. Presently, these findings 
could be defined as possible GI-disease 
 
CMV hepatitis:  
Proven disease requires abnormal liver function tests plus CMV documented in tissue 
by histopathology, immunohistochemistry, virus isolation, rapid culture, or DNA 
hybridization techniques plus the absence of other documented cause of hepatitis.  
Probable is not a recommended category for CMV hepatitis. Due to the risk for other 
confounders such as acute and chronic allograft rejection in liver transplant recipients or 
GVHD in HSCT recipients, as well as the common occurrence of drug-associated liver 
dysfunction, a probable CMV hepatitis category is not defined.  
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CMV retinitis:  
Proven disease requires typical ophthalmological signs judged by an ophthalmologist 
experienced with the diagnosis of CMV retinitis. If the presentation is atypical or an 
experienced ophthalmologist is not available, it is recommended that the diagnosis is 
supported by CMV documented in vitreous fluid by NAT (such as PCR). 
A probable disease category should not be used. 
 
CMV encephalitis and ventriculitis:  
Proven disease requires central nervous system (CNS) symptoms plus detection of 
CMV in CNS tissue by virus isolation, rapid culture, immuno-histochemical analysis, in 
situ hybridization, or (preferably) quantitative PCR.  
Probable disease requires CNS symptoms plus detection of CMV in CSF without 
visible contamination of blood (“bloody tap”) plus abnormal imaging results or 
evidence of encephalitis on EEG. 
Nephritis:  
Proven disease is defined by the detection of CMV by virus isolation, rapid culture, 
immunohistochemical analysis, or in situ hybridization in a kidney allograft biopsy 
specimen obtained from a patient with renal dysfunction together with the identification 
of histologic features of CMV infection. The detection of CMV in urine by PCR or 
culture is not sufficient for the diagnosis of CMV nephritis since asymptomatic viral 
shedding in urine is common. 
 
Cystitis:  
Proven disease is defined by the detection of CMV by virus isolation, rapid culture, 
immunohistochemical analysis, or in situ hybridization in a bladder biopsy specimen 
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obtained from a patient with cystitis together with the identification of conventional 
histologic features of CMV infection. The detection of CMV in urine by PCR or culture 
is not sufficient for the diagnosis of CMV cystitis since asymptomatic viral shedding in 
urine is common.  
 
Myocarditis:  
Proven disease is defined by the detection of CMV by virus isolation, rapid culture, 
immunohistochemical analysis, or in situ hybridization in a heart biopsy specimen 
obtained from a patient with myocarditis together with the identification of conventional 
histologic features of CMV infection.  
 
Pancreatitis:  
Proven disease is defined as the detection of CMV by virus isolation, rapid culture, 
immunohistochemical analysis, or in situ hybridization in a pancreatic biopsy specimen 
obtained from a patient with pancreatitis together with the identification of conventional 
histologic features of CMV infection.  
 
Other end-organ disease categories: 
CMV can also cause disease in other organs, and the definitions of these additional 
disease categories include the presence of compatible symptoms and signs and 
documentation of CMV by biopsy by virus isolation, rapid culture, 
immunohistochemical analysis, or in situ hybridization. 
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CMV syndrome is a disease definition that should only be used in SOT recipients. Since 
it is impossible to exclude all other causes of the clinical symptomatology described as 
CMV syndrome, a proven category cannot be defined. The definition of probable 
CMV syndrome requires detection of CMV in blood by viral isolation, rapid culture, 
antigenemia or an NAT together with at least two of the following: 
a. Fever ≥38°C for at least 2 days  
b. New or increased malaise (toxicity grade 2) or new or increased 
fatigue (toxicity grade 3) (National Cancer Institute: Common 
Terminology Criteria for Adverse Events (CTCAE), Version 4.0).  
c. Leukopenia or neutropenia on two separate measurements at least 24 
hours apart defined as: a WBC count of  3,500/μL, if the WBC count 
prior to the development of clinical symptoms was ≥ 4,000/μL or a 
WBC decrease of > 20%, if the WBC count prior to the development 
of clinical symptoms was < 4,000/μL. The corresponding neutrophil 
counts are < 1,500/μL or a decrease of more than 20% if the neutrophil 
count before the onset of symptoms was below 1,500/μL 
d. ≥ 5% atypical lymphocytes. 
e. Thrombocytopenia defined as a platelet count of < 100,000/μL if the 
platelet count prior to the development of clinical symptoms was ≥ 
115,000/mL or a decrease of > 20% if the platelet count prior to  the 
development of clinical symptoms was < 115,000/L 
f. Elevation of hepatic transaminases (ALT or AST) to 2 × upper limit of 
normal (applicable to non-liver transplant recipients)  
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Several new antiviral agents and vaccines to prevent CMV infection and/or disease are 
in clinical development [8-11]. In order for meaningful comparison of clinical 
outcomes, it is important that clinical studies of new agents use common (standardized) 
definitions regarding trial endpoints. Updating the previous definitions of CMV 
infection and disease is warranted, since transplant practices and diagnostic techniques 
have advanced and continued to evolve. It should also be recognized that some “gold 
standard” techniques never were submitted to critical assessment but have been used in 
clinical trials based on old and not necessarily well-controlled studies. It is also very 
unlikely that comparative studies between “old” and “new” diagnostic techniques will 
be performed since many diagnostic laboratories no longer perform classic virus 
isolation or rapid culture techniques. We therefore wanted to address these issues by 
adding a “probable” CMV disease category. It is likely that future studies will include 
both proven and probable CMV disease definitions in their design but the classification 
will allow the possibility to find differences in outcome between patients having 
developed these different disease categories. We are aware that there are situations not 
covered by these two categories and we therefore describe a couple of instances were 
“possible” CMV disease can be defined. At this time, however, we do not recommend 
to include these in clinical trial design until more data is available.  
The “gold standard” of CMV end-organ disease for documenting the effects of new 
agents is difficult to incorporate in current clinical trial designs since it has become 
increasingly rare [12, 13]. Use of surrogate outcomes, such as viremia, DNAemia, and 
antigenemia has been suggested by others. However, there is variability between 
different assays used for detection of CMV. Most current assays detect nucleic acids in 
a quantitative manner. A major advance during the last decade has been the introduction 
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of an international standard for CMV DNA quantitation allowing comparison of results 
from different techniques [6] although a recent report indicates that, while the standard 
is an improvement, variability between assays remains high [14, 15]. It is therefore 
strongly encouraged to use assays that have been calibrated to a standard in the clinical 
trial setting and preferably to use a central laboratory. Another need for future research 
is to define thresholds for quantitation of CMV from tissue material and this is an area 
of active investigation. Additional developments are in the field of detecting specific 
immune responses to CMV but these techniques are not ready at this time for 
widespread use and incorporation in clinical trial design.  
In SOT recipients, the “CMV-syndrome” category will be the most frequently 
documented type of CMV disease. However, the different clinical symptoms and signs 
included in the definition are very common in the immunocompromised patients. CMV 
syndrome is not a precisely defined entity, and therefore future research should focus on 
a scoring system ultimately establishing a threshold score for this entity.  
As the field evolves, the need for updates of these definitions is clear and collaborative 
efforts between scientists, regulators, and industry can provide a platform for this work.  
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Table 1. CMV disease categories and required quality of evidence 
Disease Proven Probable Possible 
Pneumonia Yes Yes (Yes) 
Gastrointestinal disease Yes Yes (Yes) 
Hepatitis Yes No No 
Retinitis Yes No No 
Encephalitis/ventriculitis Yes Yes No 
Nephritis Yes No No 
Cystitis Yes No No 
Myocarditis Yes No No 
Pancreatitis Yes No No 
Other end-organ diseases Yes No No 
Syndrome No Yes No 
 
All three categories require appropriate clinical symptoms and/or signs. 
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